By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aduro Biotech 

626 Bancroft Way
Suite 3C
Berkeley  California  94710  U.S.A.
Phone: 510-848-4400 Fax: n/a




Company News
Aduro Biotech Reports Long-Term Survival And Immune Biomarker Data From Phase 2 Clinical Trial Of Its Immuno-Oncology Regimen In Patients With Pancreatic Cancer 1/20/2015 9:04:10 AM
Aduro Biotech Announces Phase 2 Clinical Trial Results For Pancreatic Cancer Combination Immunotherapy Published In Journal Of Clinical Oncology 1/13/2015 9:32:46 AM
Berkeley's Aduro Biotech Banks $51.4 Million 1/5/2015 6:19:58 AM
Aduro Biotech Announces Preclinical Data Presented At American Association for Cancer Research Tumor Immunology And Immunotherapy Conference 12/4/2014 9:07:33 AM
Aduro Biotech Presents Updated Interim Results From Phase 1b Clinical Trial In Mesothelioma At International Mesothelioma Interest Group Conference 10/24/2014 10:51:24 AM
Aduro Biotech Announces Interim Phase 1B Clinical Data Of CRS-207 For The Treatment Of Mesothelioma Accepted For Oral Presentation At The International Mesothelioma Interest Group Conference 10/16/2014 11:23:28 AM
Berkeley's Aduro Biotech Strikes $817 Million Lung Cancer Pact With Janssen Biotech Inc. (JNJ) 10/16/2014 6:50:36 AM
Aduro Biotech’s Chief Scientific Officer, Thomas W. Dubensky, Jr., Ph.D., Featured Speaker On Action Of Vaccine Adjuvants At Keystone Symposia 10/9/2014 10:49:25 AM
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/21/2014 6:37:52 AM
Aduro Biotech Names Industry Veteran And Academic Leader, Gerald Chan, DSc To Its Board Of Directors 7/17/2014 8:05:29 AM